2012 1H: Results note

Natraceutical confirms operational improvement to June and sets profit from operations at 0.72 M€ compared to -1.54 M€ in the first half of 2011

  • After a decline of 19.5% in turnover in the first quarter of 2012, sales recovery from April to June (+3.4% vs. 2Q 2011) allowed Natraceutical to close the first half of the year with a turnover of 16.86 M€ (-10.9%).
  • The company’s EBITDA stood at 1.08 M€ as of June 2012 (-0.92 M€ in the first half of 2011). During the months of April to June, where the largest advertising investment is allocated due to the summer campaign of Forté Pharma’s Slimming segment, EBITDA stood at -0.74 M€ versus -2.02 M€ in the second quarter last year.
  • The negative evolution of Naturex’s share price in the first half of the year (-10.2%) impacted in 7.19 M€ Natraceutical’s financial result and the company closed June with a net result after interest and taxes of -8.82 M€ compared to 0.91 M€ to June 2011.
  • At the end of the semester, the value of the financial investment in Naturex stood at 63.65 M€.
  • In the first six months of the year, Natraceutical reduced its net financial debt in 9.8 M€, placing the net financial debt at the end of June at 46.82 M€.

Download original text (PDF)